Cadila Healthcare announced that the company's formulations manufacturing facility located at Baddi,
India has received an Establishment Inspection Report (EIR). The USFDA had conducted an
inspection at the facility from 15 July 2019 to 19 July 2019. The EIR report stated that the
classification of the facility is 'No Action Indicated (NAI)'
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
